Peer Reviewed
Feature Article Cardiovascular medicine
Familial hypercholesterolaemia: walking time bombs and digging for gold
Abstract
Treatment of familial hypercholesterolaemia, one of medicine’s most cost-effective measures, can delay the onset of coronary heart disease and prolong life expectancy.
Key Points
- Most GPs will have in their practice patients with heterozygous FH, whether recognised or not.
- Most adults with FH are diagnosed sporadically. FH in children remains largely undiagnosed and untreated.
- Coronary atherosclerosis in adult patients with FH can be controlled with effective LDL-C lowering, but this requires maximum doses of potent statins in combination with ezetimibe, and often resins and nicotinic acid as well.
- Referral of patients with FH to a lipid clinic with experience in this area is the preferred option for family screening, a key component of FH management.
- Ongoing management of patients with FH should be undertaken jointly by GPs and the lipid clinic.
- There is a need for improved health professional and community awareness of FH as a serious and relatively common genetic disorder for which effective treatments are available.
Purchase the PDF version of this article
Already a subscriber? Login here.